4974 TAKARA BIO INC. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4974

TSE Prime

TAKARA BIO INC.

991

JPY

-1

(-0.10%)

Dec 23, 3:30 pm JST

6.32

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

987.4

Dec 23, 5:52 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	46,086	13,952	14,159	9,547	79.3	16	May 13, 2021	J-GAAP
Mar, 2022	67,699	28,902	28,459	19,849	164.8	33	May 12, 2022	J-GAAP
Mar, 2023	78,142	20,541	20,682	16,012	133.0	42	May 11, 2023	J-GAAP
Mar, 2024	43,505	3,003	3,405	1,480	12.3	17	May 10, 2024	J-GAAP
Mar, 2025 Guidance	48,900	5,000	5,200	3,400	28.2	17	May 10, 2024	J-GAAP
YoY	+12.4%	+66.5%	+52.7%	+129.7%	+129.6%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 14, 2019	36,000	6,200	6,450	4,250	8	J-GAAP
	Nov 12, 2019	33,900	6,200	6,350	4,250	8	J-GAAP
	Feb 13, 2020	34,300	6,200	6,300	3,700	8	J-GAAP
Results	May 14, 2020	34,565	6,274	6,347	3,819	8	J-GAAP
Mar, 2021	May 14, 2020	Available in future release
	Aug 4, 2020
	Nov 10, 2020
	Feb 10, 2021
Results	May 13, 2021
Mar, 2022	May 13, 2021
	Aug 3, 2021
	Nov 9, 2021
	Feb 10, 2022
Results	May 12, 2022
Mar, 2023	May 12, 2022
	Nov 10, 2022
	Feb 9, 2023
Results	May 11, 2023
Mar, 2024	May 11, 2023
	Nov 9, 2023
Results	May 10, 2024
Mar, 2025	May 10, 2024	48,900	5,000	5,200	3,400	17	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2003	14,376	－	Available in future release
Mar, 2004	13,592	-5.5
Mar, 2005	13,685	+0.7
Mar, 2006	16,534	+20.8
Mar, 2007	20,982	+26.9
Mar, 2008	20,278	-3.4
Mar, 2009	18,913	-6.7
Mar, 2010	19,325	+2.2
Mar, 2011	18,737	-3.0
Mar, 2012	19,578	+4.5
Mar, 2013	20,564	+5.0
Mar, 2014	23,905	+16.2
Mar, 2015	25,969	+8.6
Mar, 2016	29,729	+14.5
Mar, 2017	29,375	-1.2
Mar, 2018	32,312	+10.0
Mar, 2019	35,841	+10.9
Mar, 2020	34,565	-3.6
Mar, 2021	46,086	+33.3
Mar, 2022	67,699	+46.9
Mar, 2023	78,142	+15.4
Mar, 2024	43,505	-44.3
Mar, 2025 Guidance	48,900	+12.4	5,000	+66.5	5,200	+52.7	28.2	+129.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	78,142	20,541	26.3	15.39	13.08	0.64	133.0
Mar, 2024	43,505	3,003	6.90	1.32	1.18	0.35	12.3
Mar, 2025 Guidance	48,900	5,000	10.2	2.94	2.71	0.39	28.2

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	78,142	28,902	28,459	19,849	164.8
Fiscal Year	Mar, 2023	Mar, 2022	Mar, 2022	Mar, 2022	Mar, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	36,148	14,797	14,218	9,840	81.7	33	May 12, 2022	J-GAAP
Oct - Mar, 2022	45,555	9,671	9,727	7,474	62.1	42	May 11, 2023	J-GAAP
Oct - Mar, 2023	24,389	1,593	1,807	396	3.3	17	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	29,142	4,583	4,651	2,887	24.0	17	Nov 8, 2024	J-GAAP
YoY	+19.5%	+187.7%	+157.4%	+629.0%	+628.9%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	28,902	-86	6,985	-7,071	-2,070	22,160	19.15	J-GAAP
Mar, 2023	20,541	30,204	36,897	-6,693	-4,119	49,058	37.97	J-GAAP
Mar, 2024	3,003	-11,332	1,711	-13,043	-5,233	33,171	27.36	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	32,587	10,870	10,955	8,538	70.9	53.0	Nov 10, 2022	J-GAAP
Apr - Sep, 2023	19,116	1,410	1,598	1,084	9.0	46.9	Nov 9, 2023	J-GAAP
Apr - Sep, 2024	19,758	417	549	513	4.3	10.6	Nov 8, 2024	J-GAAP
YoY	+3.4%	-70.4%	-65.6%	-52.7%	-52.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	27,619	8,533	8,525	6,057	50.3	30.9	Feb 9, 2023	J-GAAP
Jan - Mar, 2023	17,936	1,138	1,202	1,417	11.8	6.3	May 11, 2023	J-GAAP
Apr - Jun, 2023	9,176	423	509	319	2.7	4.6	Aug 8, 2023	J-GAAP
Jul - Sep, 2023	9,940	987	1,089	765	6.4	9.9	Nov 9, 2023	J-GAAP
Oct - Dec, 2023	10,618	-1,074	-1,012	-930	-7.7	-10.1	Feb 14, 2024	J-GAAP
Jan - Mar, 2024	13,771	2,667	2,819	1,326	11.0	19.4	May 10, 2024	J-GAAP
Apr - Jun, 2024	8,493	-1,634	-1,498	-1,047	-8.7	-19.2	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	11,265	2,051	2,047	1,560	13.0	18.2	Nov 8, 2024	J-GAAP
YoY	+13.3%	+107.8%	+88.0%	+103.9%	+103.9%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	8,108	-4.8	Available in future release
Jan - Mar, 2020	10,007	+0.5
Apr - Jun, 2020	6,938	-19.8
Jul - Sep, 2020	10,455	+34.0
Oct - Dec, 2020	12,156	+49.9
Jan - Mar, 2021	16,537	+65.3
Apr - Jun, 2021	15,272	+120.1
Jul - Sep, 2021	16,279	+55.7
Oct - Dec, 2021	14,108	+16.1
Jan - Mar, 2022	22,040	+33.3
Apr - Jun, 2022	14,102	-7.7
Jul - Sep, 2022	18,485	+13.6
Oct - Dec, 2022	27,619	+95.8
Jan - Mar, 2023	17,936	-18.6
Apr - Jun, 2023	9,176	-34.9
Jul - Sep, 2023	9,940	-46.2
Oct - Dec, 2023	10,618	-61.6
Jan - Mar, 2024	13,771	-23.2
Apr - Jun, 2024	8,493	-7.4
Jul - Sep, 2024	11,265	+13.3	2,051	+107.8	2,047	+88.0	13.0	+103.1

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	27,619	8,976	8,579	6,057	50.3
Fiscal Year	Dec, 2022	Mar, 2022	Jun, 2021	Dec, 2022	Dec, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	796.18	82.9	115,712	95,873	45,009	0.01	May 12, 2022	J-GAAP
Mar, 2023	931.93	86.9	129,202	112,219	57,047	0.01	May 11, 2023	J-GAAP
Mar, 2024	926.00	92.0	121,252	111,505	53,471	ー	May 10, 2024	J-GAAP
Apr - Sep, 2024	961.84	92.4	125,280	115,820	51,937	ー	Nov 8, 2024	J-GAAP

TAKARA BIO INC.(4974) Financial Results